George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Exact Bojo response:
"I don't think that is entirely true categorisation of what the govt is doing, on the contra we have worked night and day to build up our domestic lateral flow capacity"
So, acknowledging the domestic LFT capacity increase, though we knew that already!
Great find Crispy - do you have the ref numbers, the link doesn’t work for me
Thought you were in already Chris?
Promotional Twitter I get the impression was Walbrook getting a bit ahead of themselves........
Disagree
LFT wise, they have 2m capacity
1m govt (on loaned machine)
1m split 200k pw ABC-19 and 800k Visitect
I assume also they have been using the govt machine - this maybe producing ABC-19 (since that is a govt test and Abingdon seem to be on the naughty step) or Visitect test - I doubt it has been gathering dust!
Oh dear god - Walter Mitty is still playing this 'colin is my mate' story - geez, you can tell their is crap comms when this is happening!!
Sounding positive - the SP is abysmal as usual - thanks Colin and Walbrook for some truly awful PR and comms - clearly only bother when the directors want to sell.
Continues. Work through these then another load gets spewed. No chart comparisons this year I imagine.
Saudi news sound like it’ll be signing licences and little more. Happy to be corrected. Presumably no time scale for ratification? I wonder when that DRC contract was signed. I suspect before PF’s lastest badge was awarded. Waiting for ratification might have commenced many month ago.
Face value!! :) You’d be mad too. History and the SP suggests ongoing scepticism.
Just need to wait for news - we hope it should be soon.
AVCT changing from the previous 'we will sell everything we make' to 'we will increase manufacturing if demand increases' was a real dampner but hopefully we will rise above that.
ii's won't buy into ODX - it is too bouncy (generally down at the moment) due to poor comms - the rampy stuff on twitter, the very poor RNS's even on positive news and the then absurd long periods of silence. Then add directors selling on mass a few months ago, if you don't scratch the surface, you could be forgiven for thinking this company is a fraud!
Colin has mentioned a couple of times that the year end results are what he cares about, day to day movement on the SP is not - hence why I believe the SP bounces around and dies - and it has nothing to do with MM's - it is down to the company providing very little comms or updates.
Interesting - I hope with govt connections we will move onto other tests post the covid demand (which I see only reducing but not ending)
I am anticipating sepsis testing and / or a test that can distinguish between flu and covid - that would be incredibly useful longer term.
Guy changes his tune (and deletes his tweets' all the time
Can't take him seriously.
All investing is an element of chance - at a high level, ODX looks a good bet in the AIM soup:
- government contrcat of up to £374m for 1m per week (ie half our production capacity of LFT)
- also producing the ABC-19 test which we have seen is specifically mentioned in the code for the NHS APP
- the Visitect antigen LFT (Mologic) which as per Mologic updates has passed in Germany and looking for home use and in USA has received millions in funding and has had several independent reviews (as we see with Innova, company clinical studies are not worth much and always tend to be very high S&S)
- the company continues to recruit
- we have been paid the first part of the govt money
- we are actively working with the govt - packaging and choosing a test to manufacture - I know not a great shake but its money coming in and shows a relationship
Therefore, I take on board the risks and think ODX has a good opportunity to do well. The SP is largely the uncertainty that is from the lack of updates and the generally downcast updates even on positive news - frustrating but it will eventually come to fruition.
I am sure I have heard Colin mention this a couple of times, but he see's the CEO role to deliver turnover and profit and report this at the end of the year - with this being his focus, then makes it a bit clearer why the SP movement isn't really much of a concern.
I don't love that approach - something more upbeat would be better but that's my selfish view as a shareholder (and why it irked me the rampy tweeting that went on around the director sells!)
Will
If you can name me one of the following, I will bow down to your knowledge
1. Which Spanish hospital was the testing done at?
2. Who authored the Clinical Study
I still wonder why it has not been shared and peer reviewed?
Will, you must be a trading guru - we are so lucky you shar eyour thoughts on LSE for everyone.
Hey Will
You seem a bit sensitive - I was just stating that Clinical Studies always tend to be very successful - always lower when done by a third party
Agreed - ODX is low and AVCT is very high, lets see what happens now we are into the action stage of the LFT rather than the talk stage..........I look forward to AS updates
Innova's own clinical test gave themselves a sensitivity of 99% - it is on their website.
"SneakySimon - Avacta didn't do their own clinical study. You are very boring and wrong!"
Who did it then - it isn't specified on any RNS or publication. Not a single AVCT holder has been able to tell me who did it or even which Spanish hospital ran the study......
I take it all back if you can tell me?
Rocquet - AVCT's test has only been tested by themselves - nothing shared........you don't even know which Spanish hospital.
All companies when they do their own clinical studies 'happen' to come out with amazing results. Look at Innova - theirs came out at 99.8%. Then look at Roche in fact, all the other tests - always very high when they do it themself.
Now look when its independently tests it - the performance is always reduced.
I see AVCT banging on about their gold standard test, but when you compare their own clinical study to other companies clinical studies, it is about on par. So lets see how the third party studies get on first - until then, it is a good test I am sure, but as yet, not verified and not going to be accepted by UKGOV until its been tested and as per the RNS's, their is a stumbling block with the frozen samples (that no-one else has an issue with!).
You now have moved from anticipation stage to now deliver - people will be clambering for all these sales and deals promised - but I suspect that will take time. I also think AVCT's presentation being on the 21st is significant.